Search Site

Search form

Current Press Releases

All Releases
View Summary Vertex Provides Update on Ongoing Phase 3 Program for VX-661 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis
Aug 15, 2016
PDF 16.6 KB
View Summary Vertex Reports Second Quarter 2016 Financial Results
Jul 27, 2016
PDF 44.2 KB
View Summary Vertex to Announce Second Quarter 2016 Financial Results on July 27
Jul 14, 2016
PDF 8.1 KB
View Summary Vertex and Moderna Establish Exclusive Collaboration to Discover and Develop mRNA Therapeutics™ for Cystic Fibrosis
Jul 6, 2016
PDF 17.5 KB
View Summary Vertex Announces Presentations of Data for KALYDECO® (ivacaftor) and ORKAMBI® (lumacaftor/ivacaftor) at European Cystic Fibrosis Society (ECFS) Conference
Jun 10, 2016
PDF 21.7 KB
View Summary Vertex to Present at the Goldman Sachs Healthcare Conference on June 7
May 31, 2016
PDF 7.9 KB
View Summary U.S. FDA Accepts for Priority Review Supplemental New Drug Application for the Use of ORKAMBI® (lumacaftor/ivacaftor) in Children with Cystic Fibrosis Ages 6 to 11 who have Two Copies of the F508del Mutation
May 31, 2016
PDF 17.1 KB
View Summary Vertex Reports First Quarter 2016 Financial Results
Apr 27, 2016
PDF 46.2 KB
View Summary Vertex to Announce First Quarter 2016 Financial Results on April 27
Apr 15, 2016
PDF 8.1 KB
View Summary Vertex to Present at the Barclays Healthcare Conference on March 15
Mar 10, 2016
PDF 7.9 KB
View Summary Vertex Receives Australian Approval for ORKAMBI® (lumacaftor/ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Two Copies of the F508del Mutation
Mar 8, 2016
PDF 18.2 KB
View Summary Vertex Awards $1 Million in Grants to 18 Non-profit Organizations to Advance Initiatives for People Living with Cystic Fibrosis
Feb 24, 2016
PDF 16.4 KB
View Summary Vertex to Present at Upcoming Investor Conferences
Feb 9, 2016
PDF 8.1 KB
View Summary Vertex Receives Complete Response Letter from U.S. FDA for Use of KALYDECO® (ivacaftor) in People with Cystic Fibrosis Ages 2 and Older with One of 23 Residual Function Mutations
Feb 5, 2016
PDF 16.8 KB
View Summary Vertex Reports Full-Year and Fourth Quarter 2015 Financial Results
Jan 27, 2016
PDF 52.2 KB
View Summary Health Canada Approves PrORKAMBI® (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cystic Fibrosis for People Ages 12 and Older with Two Copies of the F508del Mutation
Jan 26, 2016
PDF 18.4 KB
View Summary Vertex Outlines 2016 Business Priorities to Support the Discovery and Development of New Transformative Medicines for the Treatment of Cystic Fibrosis and Other Serious Diseases
Jan 10, 2016
PDF 39.1 KB
View Summary Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth Quarter and Full Year 2015 Financial Results
Jan 5, 2016
PDF 8.2 KB
Showing 1-18 of 18 Page: 1